MetaCap

ACADIA Pharmaceuticals (ACAD) vs Bausch Health Companies (BHC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Bausch Health Companies (BHC) has outperformed ACADIA Pharmaceuticals (ACAD) over the past year, gaining 36.3% versus a loss of 27.4%. Over five years, ACAD leads with a -8.9% price change compared with -67.4% for BHC. Bausch Health Companies is the larger company by market cap ($3.08 billion vs $2.96 billion), about 1.0 times the size, while ACADIA Pharmaceuticals is growing revenue faster (+11.9% vs +6.7%).

On valuation, Bausch Health Companies trades at a lower forward P/E (1.9x vs 15.8x for ACADIA Pharmaceuticals). ACADIA Pharmaceuticals converts more of its revenue into profit, with a net margin of 36.5% versus 1.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ACAD-27.38%BHC+36.32%
+52%+9%-34%
Nov 21, 20251 yearNov 20, 2026
ACAD-10.65%BHC-68.40%
+76%-8%-91%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ACAD versus BHC key metrics
MetricACADBHC
Share price$17.11$8.22
Market cap$2.96B$3.08B
1-day change-2.73%-3.97%
YTD return-35.94%+18.27%
1-year return-27.38%+36.32%
5-year return-8.94%-67.45%
P/E ratio (TTM)8.07—
Forward P/E15.751.89
EPS (TTM)$2.12$-2.26
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$1.07B$10.27B
Revenue growth (YoY)+11.87%+6.66%
Net income (latest FY)$391.00M$157.00M
Gross margin91.69%—
Operating margin9.78%17.66%
Net margin36.49%1.53%
52-week high$30.96$9.04
52-week low$15.86$4.33
Distance from 52-week high-44.74%-9.07%
Analyst consensusbuyhold
Avg. price target upside+77.21%+2.19%
Average volume2.18M3.16M
Shares outstanding172.83M374.27M
Employees79620,300
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • BHC has outperformed ACAD by 63.7 percentage points over the past year.
  • ACADIA Pharmaceuticals is more profitable, keeping 36.5 cents of every revenue dollar as net income versus 1.5 cents for Bausch Health Companies.
  • ACADIA Pharmaceuticals grew revenue faster in its latest fiscal year (+11.87% vs +6.66%).

About ACADIA Pharmaceuticals

ACAD stock →

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.

Health Care · Biotechnology: Pharmaceutical Preparations · 796 employees

About Bausch Health Companies

BHC stock →

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company.

Health Care · Biotechnology: Pharmaceutical Preparations · 20,300 employees

ACAD vs BHC FAQ

Which is bigger, ACADIA Pharmaceuticals or Bausch Health Companies?

Bausch Health Companies (BHC) is larger, with a market capitalization of $3.08B compared with $2.96B for ACADIA Pharmaceuticals (ACAD).

Which stock has performed better over the past year, ACAD or BHC?

BHC returned +36.32% over the past 12 months, compared with -27.38% for ACAD (price return, excluding dividends). Past performance does not predict future results.

Are ACADIA Pharmaceuticals and Bausch Health Companies in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons